NASDAQ:MRUS - Merus Stock Price, Forecast & News

Merus trades on the NASDAQ under the ticker symbol "MRUS."

Merus NV (NASDAQ:MRUS) released its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.07. The biotechnology company earned $9.02 million during the quarter, compared to the consensus estimate of $7.79 million. Merus had a negative return on equity of 40.56% and a negative net margin of 90.21%. View Merus' Earnings History.

Merus is scheduled to release their next quarterly earnings announcement on Wednesday, April 1st 2020. View Earnings Estimates for Merus.

6 Wall Street analysts have issued 12-month price objectives for Merus' shares. Their forecasts range from $16.00 to $35.00. On average, they expect Merus' stock price to reach $24.00 in the next year. This suggests a possible upside of 42.0% from the stock's current price. View Analyst Price Targets for Merus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merus.

News headlines about MRUS stock have been trending extremely negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Merus earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Merus.

Some companies that are related to Merus include Ligand Pharmaceuticals (LGND), Amneal Pharmaceuticals (AMRX), Theravance Biopharma (TBPH), Corcept Therapeutics (CORT), Innoviva (INVA), Endo International (ENDP), BELLUS Health (BLUSF), TG Therapeutics (TGTX), Esperion Therapeutics (ESPR), Y-mAbs Therapeutics (YMAB), Intra-Cellular Therapies (ITCI), Nabriva Therapeutics (NBRV), Dicerna Pharmaceuticals (DRNA), Supernus Pharmaceuticals (SUPN) and Madrigal Pharmaceuticals (MDGL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), Enterprise Products Partners (EPD), AT&T (T), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), ImmunoGen (IMGN), MacroGenics (MGNX), Micron Technology (MU) and SCYNEXIS (SCYX).

(MRUS) raised $64 million in an initial public offering (IPO) on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MRUS stock can currently be purchased for approximately $16.90.

Merus has a market capitalization of $395.60 million and generates $37.14 million in revenue each year. The biotechnology company earns $-28,660,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Merus employs 98 workers across the globe.View Additional Information About Merus.

The official website for Merus is http://www.merus.nl/.

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]